Insulet Corporation $PODD Shares Acquired by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. grew its stake in Insulet Corporation (NASDAQ:PODD) by 17.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,518 shares of the medical instruments supplier’s stock after purchasing an additional 5,392 shares during the period. Geneos Wealth Management Inc. owned approximately 0.05% of Insulet worth $9,327,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Allspring Global Investments Holdings LLC boosted its stake in shares of Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock valued at $1,376,000 after buying an additional 1,867 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Insulet by 85.1% in the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier’s stock valued at $236,000 after buying an additional 412 shares in the last quarter. QRG Capital Management Inc. boosted its stake in shares of Insulet by 75.6% in the first quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier’s stock valued at $533,000 after buying an additional 874 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in Insulet by 225.4% during the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier’s stock worth $408,000 after purchasing an additional 1,075 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its position in Insulet by 2.6% during the first quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier’s stock worth $2,156,000 after purchasing an additional 210 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Insulet in a research report on Friday, May 16th. Citigroup reiterated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Finally, Royal Bank Of Canada boosted their target price on Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $335.12.

Insulet Stock Performance

Insulet stock opened at $352.82 on Wednesday. The firm has a market capitalization of $24.83 billion, a P/E ratio of 107.24, a PEG ratio of 2.90 and a beta of 1.36. The stock has a fifty day moving average price of $309.32 and a 200 day moving average price of $290.77. Insulet Corporation has a 52 week low of $217.82 and a 52 week high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.